人甲状腺癌细胞CAL-26
BLUEFBIO™ Product Sheet
|
细胞名称 |
人甲状腺癌细胞CAL-26 |
|
|
|
货物编码 |
BFN60810161 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 3类 |
||
|
培养体系 |
90%DMEM+10%FBS+1%三抗 |
|||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
|
简介 |
人甲状腺癌细胞CAL-26取自70岁女性供体。该细胞源于DSMZ |
|||
|
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Doubling time: ~24 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis. |
|||
|
基因突变 |
Heterozygous for CREBBP p.Glu1541Ter (c.4621G>T) (PubMed=30737244). Homozygous for EP300 p.Asp1485fs (c.4454delA) (PubMed=30737244). Homozygous for KRAS p.Gly12Arg (c.34G>C) (PubMed=23833040; PubMed=30737244). Homozygous for NF2 p.Glu215Ter (c.643G>T) (PubMed=30737244). Homozygous for TP53 p.Ala161Asp (c.482C>A) (ClinVar=VCV000422295) (PubMed=30737244). |
|||
|
HLA信息 |
/ |
|||
|
STR信息 |
Amelogenin X CSF1PO 9,12 D3S1358 16 D5S818 9,12 D7S820 10 D8S1179 13 D13S317 12 D16S539 12,13 D18S51 16 D21S11 32.2 FGA 19 TH01 7,9 TPOX 8,9 vWA 16 |
|||
|
参考文献 |
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953 Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin. Cancer Res. 25:3141-3151(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) |
|
||
